Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.

Human gene therapy - 20 Mar 1997

Pyles R B, Warnick R E, Chalk C L, Szanti B E, Parysek L M

Abstract excerpt

A promising approach for the therapeutic treatment of brain tumors utilizes replication-competent, neuroattenuated herpes simplex virus-1 (HSV-1) mutants. This approach requires mutation of HSV-1 to eliminate killing of normal, nondividing cells of the brain (e.g., neurons). We have generated a HSV-1 double-mutant, designated 3616UB, by interrupting the uracil DNA glycosylase (UNG) gene in a previously studied...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Chlorocebus aethiops
Share to Genetic Vectors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to In Situ Hybridization, Fluorescence

Share to Lac Operon

Share to Mutation

Source

Identifiers

PMID: 9095405
DOI: 10.1089/hum.1997.8.5-533

Genes

UNG

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.PMID 9095405Read ↗

Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant.Semantic proximity Read ↗

Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.Semantic proximity Read ↗

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.Semantic proximity Read ↗

Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir.Semantic proximity Read ↗

An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.Semantic proximity Read ↗

Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant.Semantic proximity Read ↗

Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.Semantic proximity Read ↗

Oncolytic herpes simplex virus vectors for cancer virotherapy.Semantic proximity Read ↗

Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved TolerabilitySemantic proximity Read ↗

Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma.Semantic proximity Read ↗

Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats.Semantic proximity Read ↗

Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.